New Prostate Cancer Screening Trial Launched in the UK
A significant prostate cancer screening trial has been initiated in the UK, aiming to find improved methods for detecting the disease. Recently, general practitioners began sending out invitations to men for participation in this expansive study, which is the largest of its kind seen in decades.
The Transform trial, backed by £42 million from Prostate Cancer UK and the National Institute for Health and Care Research, is noteworthy. Chief investigator Hashim Ahmed remarked, “Transform is truly groundbreaking… today marks a crucial step towards obtaining the results that men need urgently for safer and more effective prostate cancer diagnoses, allowing us to explore the potential of prostate cancer screening in the UK.”
The study seeks to enroll men between the ages of 50 and 74, with black men being eligible from the age of 45 due to their doubled risk of prostate cancer. While voluntary participation isn’t an option, Prostate Cancer UK encourages those receiving invitations to engage.
The trial aims to explore the combination of rapid MRI scans of the prostate with prostate-specific antigen (PSA) blood tests to enhance the precision of cancer diagnoses. Currently, men over 50 can request PSA tests, which identify high protein levels in the blood. However, this method has shown inconsistencies, often identifying cancers that wouldn’t need treatment while overlooking others that are critical.
Additionally, the trial plans to incorporate spit tests that analyze DNA from saliva to potentially improve the accuracy compared to PSA testing. Matthew Hobbs, the research director at Prostate Cancer UK, expressed concerns regarding current diagnostic methods, stating they frequently miss aggressive cancers and cause unnecessary harm. He noted, “We hear from men diagnosed late, whose lives could have been saved with early screening. Many end up facing incontinence or impotence from treatments they didn’t need, and that’s the harm we must work to prevent.”
‘If we want to stop 12,000 men dying early every year, it’s the obvious solution’
Danny Burkey, a 60-year-old from West Yorkshire who is terminally ill with prostate cancer, emphasized the importance of regular screening. Diagnosed four years ago, by which time the cancer had spread to his bones, he believes earlier detection could have changed his situation. “I think a screening program would be a game changer. If you want to prevent men from ending up in my position—and to stop 12,000 early deaths yearly—it’s a clear solution,” he stated.
The trial’s launch occurs just ahead of the anticipated announcement from the National Screening Committee (NSC), which advises the NHS on whether to advocate for screening for prostate cancer, the most prevalent cancer among men in the UK. Previous evaluations of the NSC indicated that the drawbacks of screening had surpassed its advantages.
Initial findings from the Transform trial are expected within approximately two years, at which point the study may expand to include up to 300,000 men across the UK.
